Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Changes in laboratory and DXA parameters in multiple myeloma patients treated with romosozumab. | M0 | M6 | M12 | p-value: 25 (OH) vitamin D (ng/mL), median (IQR) | 27.5 (26.0-45.9) | 43 (33.0-44.6) | 45.4 (35.9-56.1) | .090

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

Observational study · JBMR Plus · 2025

Original publication title

Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

Mariana Diz Lopes; Francesco Pollastri; Francesca Mastropaolo; Rosanna Somma; Mattia Tugnolli; Emma Pasetto; Camilla Benini; Valeria Messina; Davide Gatti; Ombretta Viapiana; Maurizio Rossini; Elena Marchetti; Martina Tinelli; Giovanni Adami

© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO.

A significant BMD increase was observed at the LS (+5.8%, p = .048), FN (+4.2%, p = .020), and TH (+3.3%, p = .002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p = .006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (−53.6%, p = .060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p = .020 and p = .022).

No significant changes occurred in immunoglobulins, M-protein, or light chains. β2-microglobulin decreased at month 12 (from 2.35 to 2.1 mg/L, p = .042), but the overall trend was not significant (p = .092). Failure load increased at month 6 (p = .033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period.

These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.

Authors’ abstract

Abstract

Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO.

A significant BMD increase was observed at the LS (+5.8%, p = .048), FN (+4.2%, p = .020), and TH (+3.3%, p = .002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p = .006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (−53.6%, p = .060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p = .020 and p = .022).

No significant changes occurred in immunoglobulins, M-protein, or light chains. β2-microglobulin decreased at month 12 (from 2.35 to 2.1 mg/L, p = .042), but the overall trend was not significant (p = .092). Failure load increased at month 6 (p = .033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period.

These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.

Publication and source details

Original title: Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

Mariana Diz Lopes; Francesco Pollastri; Francesca Mastropaolo; Rosanna Somma; Mattia Tugnolli; Emma Pasetto; Camilla Benini; Valeria Messina; Davide Gatti; Ombretta Viapiana; Maurizio Rossini; Elena Marchetti; Martina Tinelli; Giovanni Adami

JBMR Plus · 2025

Corresponding author: Giovanni Adami, Rheumatology Section, Department of Medicine, University of Verona, Pz Scuro 10, 37134 Verona, Italy (giovanni.adami@univr.it).© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:11:15.115766+00:00

DOI: 10.1093/jbmrpl/ziaf144 · PMC12452266